Q-omics provides the consensus-scored GOLGA8S profile across patient tissues and cancer cell-line models. GOLGA8S expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GOLGA8S is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GOLGA8S RNA expression shows 14,271 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where GOLGA8S shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8S — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8S survival associations across molecular data types. GOLGA8S RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8S RNA expression–survival associations across cancer types. High GOLGA8S expression shows unfavorable associations in UVM, LUSC and KIRC, but favorable associations in LUAD, MESO and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for GOLGA8S RNA expression.
This table summarizes GOLGA8S tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8S. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8S shows lower tumor expression in COAD, THCA, BRCA, STAD and UCEC and higher tumor expression in KIRC. The KIRC box plot shows higher GOLGA8S RNA expression in tumor versus normal tissue (log2 FC = +0.039, t-test p < 0.001).
This table shows molecular features associated with GOLGA8S in patient tissues and cancer cell lines. In patient samples, GOLGA8S shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA8S RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
